Skip to navigation menu Skip to content
Informational Alert

Learn about progress on health equity and anti-racism efforts in Seattle Children’s second quarterly report.

News and Updates

New Lab Hire

November 15, 2021

The Vitanza Lab is excited to announce the hire of a new research scientist, Michael Meechan, who has years of experience working with pediatric cancer models and CAR T cell studies in Seattle Children's Jensen Lab and Seattle Children's Therapeutics. His expertise in testing targeted cellular therapies and directing large in vivo studies immediately compliments the direction and skills within the Vitanza Lab and will allow growth of our programs. His presence will help accelerate our work and our collaborations with national and international partners aiming to cure malignant pediatric CNS tumors.

Dr. Nicholas Vitanza was interviewed by Drew Amorosi of Healio

October 6, 2021

Dr. Nicholas Vitanza was interviewed by Drew Amorosi of Healio to discuss the preliminary findings of his CAR T cell trial BrainChild-01 that were published in the journal Nature Medicine (September 2021). City of Hope's Leo Wang, MD, PhD provides a commentary on Dr. Vitanza's study and results.

Dr. Nicholas Vitanza was interviewed by News Nation

September 28, 2021

Dr. Nicholas Vitanza was interviewed by News Nation to discuss the current state of national pediatric cancer funding in the United States and the goals of his lab. He also focused on the tolls of current cancer therapies.

Dr. Vitanza shared that, “Unfortunately, for almost all pediatric cancers, the initial therapy is some type of surgery. Pretty commonly, you have radiation afterward. And then you get cytotoxic, old-fashioned chemotherapy that does a lot of damage to the body. So children may have loss of their normal growth, infertility, nausea, and headaches. And these are effects that they have during their treatment, but then continue for the rest of their life. And so by the time they’re adults, most pediatric cancer survivors have multiple chronic illnesses. In my lab, we look at immunotherapy and targeted genetic therapies that we can give to children that are really specific and personalized for their tumor. And hopefully, one day by doing this will avoid all the more toxic therapies."

Vitanza Lab Joins Seattle Children’s Research Institute

July 1, 2021

Dr. Nicholas Vitanza and his team of researchers have joined Seattle Children’s Research Institute, bringing cutting-edge research to finding better treatments and cures for aggressive pediatric brain and spinal cord tumors.

The collaboration will leverage the missions and strengths of the Vitanza Lab and Seattle Children’s Research Institute, as well as the clinical capabilities of Seattle Children’s to mitigate the impact of diseases such as diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma H3 K27M-mutant (DMG) and atypical teratoid rhabdoid tumor (ATRT).

“It has been a decade-long dream to direct a laboratory focused on curing pediatric central nervous system tumors,” Vitanza said. “I have only been able to get to this point thanks to the support of my family, the generosity of so many patients and advocates and the daily collaborations among our pediatric neuro-oncology team members. We dedicate our work to all the affected patients still searching for options, and we will work tirelessly so that we can live in a world where all pediatric CNS tumors have cures.”

The new lab team is located at the Ben Towne Center for Childhood Cancer Research at 1100 Olive Way in downtown Seattle.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies